Key clinical point: The risk of sudden cardiac death with individual antipsychotics in patients with schizophrenia varies across age groups; patient age should be considered in risk-benefit evaluation.
Major finding: Exposure to zotepine significantly increased the risk of sudden cardiac death within the 14-day case period in patients younger than 45 years (adjusted relative risk [aRR], 2.68; P = .046). Exposure to flupentixol and risperidone significantly increased the risk of sudden cardiac death in patients aged 45-65 years (aRR, 5.30; P = .004 and aRR, 1.68; P = .01, respectively). There was no association between exposure to antipsychotic agents and sudden cardiac death risk in patients older than 65 years.
Study details: A case-crossover, nationwide population-based cohort involving 1,836 schizophrenia patients with sudden cardiac death.
Disclosures: The study was supported by the Ministry of Science and Technology, Taiwan and Taipei City Hospital. The authors reported no conflicts of interest.
Chen PH et al. Psychiatry Clin Neurosci. 2020 Jul 17. doi: 10.1111/pcn.13116.